Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy

• DOI: 10.1093/jnci/djg043
• Publication Date: 2003-09-16T16:57:56Z
• Authors: A. V. D'Amico; J. W. Moul; P. R. Carroll; L. Sun; D. Lubeck; M.-H. Chen
• Keywords: Biochemical recurrence; Clinical endpoint

Background: The relationship between prostate-specific antigen (PSA)–defined recurrence and prostate cancer–specific mortality remains unclear. Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is surrogate end point for by analyzing two multi-institutional databases. Methods: Baseline, treatment, follow-up information was compiled on cohort of 8669 patients with cancer treated surgery (5918 men) or (2751 from January 1, 1988, through 2002, localized locally advanced, non-metastatic cancer. We used Cox regression analysis to test whether PSA-DT prognostic factor independent treatment received. All statistical tests were two-sided. Results: statistically significantly associated all-cause (all PCox<.001). However, received not PSA-defined disease less than 3 months (PCox = .90) more .28) when controlling specific value PSA-DT. Furthermore, recurrence, (median 6 years; hazard ratio 19.6, 95% confidence interval 12.5 30.9). Conclusion: A it appear be points therapy. recommend consideration given initiating androgen suppression at delay imminent onset metastatic bone disease.